Rezulin Lawsuit News

BREAKING NEWS!!
September 8, 2003 - Rezulin Lawsuits May Be Getting Harder to Fight Off
New findings published in the Mayo clinic Proceedings show that diabetes drugs may cause heart failure and cause fluid buildup in some patients. Read Full Article...

April 22, 2003 - Pfizer must defend Rezulin lawsuit
An appeal court reinstated a Rezulin lawsuit that was dismissed in October 2001 in a lower court. The Rezulin lawsuit alleged that Pfizer’s Warner-Lambert unit hid Rezulin safety risks and continued to aggressively market Rezulin despite the serious liver damages being reported. Rezulin class action lawsuit status is currently being sought for the damages suffered by Rezulin patients.

April 22, 2003 - Rezulin fraud suit surfaces again
Rezulin Type II diabetes drug was seen as progress in treatment options when it was first introduced to the market in 1997. Forced to make Rezulin labeling changes several times, Rezulin was associated to liver failure and liver injury, leading up to the March 2000 announcement of a Rezulin recall.

A fraud suit was brought against Rezulin drug makers by health insurance companies that charged the Rezulin company continued to claim it was safe despite reporting to the FDA that 31 Rezulin users had died in a 6-month period in 1998 and that the Rezulin company continued to lie as more and more adverse Rezulin reports were made.

A Southern District of New York judge had dismissed the Rezulin case in October 2001. Now, the 2nd U.S. circuit Court of Appeals has reversed the decision. The 2nd Circuit court disagreed with the previous judge’s decision, a victory for Rezulin users that had suffered serious and deadly Rezulin side effects.

Contact a Rezulin Lawyer for more lawsuit information

April 18, 2003 - Hispanics informed of Rezulin lawsuit rights
A high number of diabetic patients that used Rezulin prior to the March 2000 recall have been filing Rezulin lawsuits for the deadly and serious effects Rezulin caused. A June 2002 L.A. Times article was written stating legal documents exist showing that Warner Lambert targeted Latinos while marketing Rezulin, as well as paying doctors to have their diabetic patients switch to using Rezulin. Now, Hispanic Rezulin patients are becoming better informed of how the judicial system can help recover damages for the serious Rezulin side effects suffered.

April 3, 2003 - Manhattan jury rules against Rezulin company
A $2 million verdict favored a former Rezulin patient that suffered Rezulin side effects, unanimously deciding there was “clear and convincing” evidence showing Warner-Lambert misrepresented or omitted Rezulin material information to physicians. At the time of the Rezulin recall there had been around one hundred people that either died or suffered from acute liver failure that required liver transplant because of Rezulin diabetes drug. Pfizer (which acquired Warner-Lambert in June 2000) is appealing the Rezulin decision. The world’s largest drug maker, Pfizer has had thousands of Rezulin lawsuits filed against the company.

March 31, 2003 - Rezulin class action lawsuit denied
In September 2002, U.S. judge denied a nationwide Rezulin class action lawsuit and now a California appeals court denied a Rezulin class action lawsuit for California residents as well. Although this may appear a small victory for Pfizer, the world’s largest drug company has had thousands of Rezulin lawsuits filed against them, paying $11.5 million, $23.6 million, and $2 million for Rezulin lawsuits the company lost, in addition to paying $43 million to settle.

A 1998 Public Citizen survey found the FDA could require manufacturers to conduct phase IV studies as a condition of approval. According to the reports, at least one phase IV study was required for 195 of 306 new drugs approved by the FDA during the 1990s, but just 11 of the 195 Phase IV studies had been completed. This pertains to the safety of Rezulin because a complete clinical trial was not completed prior to the FDA approval of the diabetes drug due to the "fast track" method used on the drug. After Rezulin was approved, official negotiated a nonbonding pledge from Warner-Lambert to start a new study to assess Rezulin's effect on patients who had preexisting heart disease evidence. Few patients were enrolled, and this study was never completed.